FIG 2.

Prognostic impact of minimal residual disease (MRD) levels at the end of consolidation (EOC) (A-D) and after MARMA (E), as shown by Kaplan-Meier estimates of disease-free survival (DFS): EOC MRD for all patients (A), patients treated with protocol IB (B), patients treated with araC, daunorubicin, etoposide (ADE)/mitoxantrone, araC, etoposide (MAE) (C), and for all patients with MRD at EOI and EOC (D) and MRD after MARMA for all patients (E). Neg, MRD-negative; Interm, MRD-intermediate (< 5 × 10⁻⁴); High, MRD-high (≥ 5 × 10⁻⁴). (D): Neg, MRD-negative at EOI and EOC; New Neg, MRD-positive at EOI and MRD-negative at EOC. For (A-D), One MRD-negative patient treated with ADE/MAE was excluded from these analyses due to missing data on first complete remission (CR1). For (E), One MRD-intermediate patient was excluded from this analysis due to missing data on CR1.